The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF- antibody infliximab
Open accessAbstract
OBJECTIVES: Anti-tumour necrosis factor therapy with infliximab has been shown to improve signs and symptoms of patients with active ankylosing spondylitis (AS). The objective of this article was to study the effect of infliximab on structural changes in AS over 4 yrs. METHODS: Conventional radiographs of the cervical and the lumbar spine of 33 AS patients at baseline (BL), after 2 (FU1) and after 4 yrs (FU2) of infliximab therapy were scored by the modified Stokes ankylosing spondylitis spinal score (mSASSS). Definite baseline damage was defined when at least one syndesmophyte (mSASSS >/=2) was seen. Definite radiographic progression was defined as a change from 0 or 1 to syndesmophytes or ankylosis (mSASSS >/=2). RESULTS: The mean change over 4 yrs was 1.6 +/- 2.6 mSASSS units (P = 0.001), (0.9 +/- 2.3 for BL-FU1 vs 0.7 +/- 1.6 for FU1-FU2). This is less radiographic progression in comparison with published data from the OASIS cohort (4.4 within 4 yrs). Definite radiographic progression was found in 10/33 (30.3%) patients for BL-FU2. Patients with definite damage at BL developed more chronic changes at FU2 (2.3 +/- 3.1, P = 0.003) than those with no damage at BL (0.7 +/- 1.5, P = 0.08). Four out of seven patients with no damage at BL showed radiographic deterioration after 4 yrs. The change of the mean mSASSS in comparison with BL was significantly different after 2 (P = 0.007) but not after 4 yrs of infliximab therapy. CONCLUSIONS: There is some radiographic progression after 2 and 4 yrs of infliximab therapy in AS patients. A comparison with the historical OASIS cohort suggests that infliximab may decelerate progression of structural changes. Larger studies are needed to confirm this finding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Osteoblast Differentiation by Tumor Necrosis Factor-α*
Gilbert, L., He, X., Farmer, P., Boden, S., Kozlowski, M., Rubin, J., & Nanes, M. S. (2000) · Endocrinology · doi:10.1210/endo.141.11.7739 · Cited by 555
Cited by
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Self-citationHeijde, D. V. D., Landewé, R., Baraliakos, X., Houben, H., Tubergen, A. V., Williamson, P., Xu, W., Baker, D., Goldstein, N., & Braun, J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23901 · Cited by 514
Self-citationvan der Heijde, D., Salonen, D., Weissman, B. N., Landewé, R., Maksymowych, W. P., Kupper, H., Ballal, S., Gibson, E., Wong, R., & the Canadian (M03-606) study group and the ATLAS study group (2009) · Arthritis Research & Therapy · doi:10.1186/ar2794 · Cited by 413
Baraliakos, X., Haibel, H., Listing, J., Sieper, J., & Braun, J. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202698 · Cited by 305
Self-citation
Metadata
- Authors
- Baraliakos, X., Listing, J., Brandt, J., Haibel, H., Rudwaleit, M., Sieper, J., & Braun, J.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-06-27
- Volume
- 46
- Issue
- 9
- Pages
- 1450-1453
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2276591334
- Cited by
- 178
- References
- 1
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF- antibody infliximab. https://app.cochat.ai/papers/10.1093/rheumatology/kem166
- The paper
- Baraliakos, X., Listing, J., Brandt, J., Haibel, H., Rudwaleit, M., Sieper, J., & Braun, J. (2007). Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF- antibody infliximab. Rheumatology. https://doi.org/10.1093/rheumatology/kem166
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.